RIGL Q3 2021 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$517M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$22M+17.2% YoY

Gross Profit

$21M99.3% margin

Operating Income

-$20M-91.8% margin

Net Income

-$21M-97.3% margin

EPS (Diluted)

$-1.20

QoQ Revenue Growth

-18.0%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$187M

Total Liabilities

$137M

Stockholders' Equity

$50M

Cash & Equivalents

$30M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$22M	$18M	+17.2%
Gross Profit	$21M	$18M	+17.2%
Operating Income	-$20M	-$14M	-43.6%
Net Income	-$21M	-$14M	-47.8%

Revenue Segments

Gross Product

$21M49%

Product

$16M38%

Contract Revenues From Collaborations

$5M11%

License

$2M6%

Development Milestones

$2M4%

Government Contract

$1M2%

Research And Development Services And Others

$225,0001%

Discounts And Allowances

-$5M-11%